A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives
Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Obesity and hypertension are independent risks for congestive heart failure (CHF) and chronic
kidney disease. In obesity induced hypertension, the most common cause of human essential
hypertension, the potential importance of mineralocorticoid receptor blockade has not been
widely investigated. We propose to test the hypothesis that eplerenone reduces metabolic
demand, improves cardiac function and attenuates glomerular hyperfiltration and
microalbuminuria in obese patients. Our specific aims are to assess changes in basal
metabolic rate, cardiac and renal function in obese hypertensive subjects treated with
eplerenone compared to amlodipine.